Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of neuromyelitis optica spectrum disorder based on the recent guidelines in 2015~* Expanded disability status scale between 0 and 7~* Age between 18 and 50 years old~Exclusion Criteria:~* Pregnancy or lactation during the study~* Deciding to leave the study by patient~* Lack of consent to enter the study~* Lack of cooperation for follow up~* Severe side effect of the medication~* Treatment with other immunosuppressant medications (including but not limited to cyclophosphamide, mycophenolate mofetil, methotrexate, others) within two months before intervention~* Taking any other immunosuppressant or other type of medication (including herbal drugs) without permission of the physician during the study.~* Presence of other autoimmune disease (including but not limited to Behcet disease, systemic lupus erythematosus, rheumatoid arthritis, and others)~* Presence of liver disorders~* Presence of hematologic disorders~* Presence of heart failure~* Receipt of a live vaccine within 4 weeks prior to intervention~* Previous treatment with Azathioporine or Rituximab~* History of HIV, hepatitis B, or hepatitis C~* Ongoing daily steroid use~* History of severe allergic or anaphylactic reaction to monoclonal antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Azathioprine (Type: EXPERIMENTAL): Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
- Rituximab (Type: EXPERIMENTAL): Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).